Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Serina Therapeutics (SER) just unveiled an announcement.
AgeX Therapeutics, Inc. has successfully completed a strategic financial restructuring through a series of transactions, resulting in the acquisition of additional funding, amendments to existing convertible notes, and the assumption of rights and obligations under various agreements by its subsidiary. These moves have culminated in a merger with Serina Therapeutics, Inc., making Serina a wholly owned subsidiary of AgeX, now renamed Serina Therapeutics, Inc. This merger is a tax-free reorganization, and the combined entity focuses on developing Serina’s drug product candidates. Post-merger, AgeX’s stock symbol has changed to “SER” on the NYSE American exchange, reflecting the new identity and future direction of the company.
Find detailed analytics on SER stock on TipRanks’ Stock Analysis page.
